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emphasize that the MCDA approach worked not only in their
pilot but also in the Hungarian real-world setting. It is indeed
worth developing for use by other payers and HTA bodies.
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In the paper “AQuestionnaire to Assess the Relevance and Credibility of Observational Studies to InformHealth Care DecisionMaking: An ISPOR-
AMCP-NPC Good Practice Task Force Report” published in Value in Health, Volume 17 (March/April 2014), pages 143-6, the following
errors occurred
 Page 146: The title of Table 1 incorrectly referred to “a prospective observational study”. The correct wording is: “Table 1 –
Questionnaire to assess the relevance and credibility of an observational study.”
 Page 146: Question 3 under relevance was incorrectly scored. The correct scoring to the question “Are the outcomes relevant?”
is as follows: A “Yes” answer is a strength. A “No” answer is a weakness.
 Page 153: In the top right-hand paragraph, the word “is” was paginated incorrectly. The sentence should read: “Credibility is
enhanced if the authors indicate…”
